Abstract:In contrast to older children and adults, premature neonates have decreased sensitivity to carbon dioxide and often experience hypoxic ventilatory depression. This can result in deleterious and prolonged periods of hypoventilation and apnea in response to hypoxemia. Caffeine is a trimethylxanthine which stimulates the respiratory control centers in the medulla through competitive inhibition of adenosine. This increases the ventilatory responsiveness to carbon dioxide and attenuates central hypoxic ventilatory depression. For this reason, caffeine is a commonly prescribed medication administered to many premature neonates in the neonatal intensive care unit (NICU). 1 Other pharmacological effects of caffeine include enhanced diaphragmatic contractility, mild diuresis, and increased minute ventilation. Through these physiologic effects and others, caffeine has substantially reduced common morbidities among premature neonates including apnea of prematurity, bronchopulmonary dysplasia (BPD), and patent ductus arteriosus (PDA). 2 Most importantly, neonates who receive caffeine have better neurodevelopmental outcomes (e.g., less cerebral palsy and cognitive delays) and a decreased incidence of severe retinopathy of prematurity (ROP). 2,3 When considering all the medications administered in the NICU, caffeine has played a very prominent role in improving important neonatal outcomes. Caffeine has a wider therapeutic index and fewer side effects compared to other methylxanthines such as theophylline and aminophylline. 4,5 Despite the profound impact that caffeine has had on the care of premature neonates, the dosing and timing of caffeine administration has changed little since the initial trials of this groundbreaking medication several decades ago. 6 In addition, despite the widespread use of caffeine, BPD, neurodevelopmental impairment, ROP, and other morbidities continue to occur frequently in premature neonates. 7 Although the efficacy, effectiveness, and safety of caffeine are well established, questions remain about of how clinicians can devise strategies to maximize the benefits. A post hoc analyses of the Caffeine of Prematurity (CAP) Trial in 2010 demonstrated that the duration of positive pressure ventilation was significantly less with earlier treatment (started at 3 days, suggesting that earlier initiation of caffeine therapy may further improve neonatal outcomes. 8 Subsequent large cohort studies, small randomized controlled trials, and metanalyses have favored earlier caffeine administration. However, how early is too early?

The Effect of Long Term Caffeine Treatment on Hypoxic-Ischemic Brain Damage in the Neonate

Caffeine Prevents Hyperoxia-Induced Lung Injury in Neonatal Mice Through NLRP3 Inflammasome and NF-κB Pathway.

Impact of Early- and High-Dose Caffeine on the Cerebellum Development in Newborn Rats

Caffeine Citrate for Apnea of Prematurity: A Prospective, Open-Label, Single-Arm Study in Chinese Neonates

Caffeine treatment started before injury reduces hypoxic–ischemic white-matter damage in neonatal rats by regulating phenotypic microglia polarization

Perinatal Caffeine Administration Improves Outcomes in an Ovine Model of Neonatal Hypoxia-Ischemia

Early versus late caffeine and/or non‐steroidal anti‐inflammatory drugs (NSAIDS) for prevention of intermittent hypoxia‐induced neuroinflammation in the neonatal rat

Protective Effects of Early Neonatal Methylxanthine Treatment on Cognitive and Language Outcomes in Premature Infants with and without High-Risk Perinatal Factors

Maternal low-dose caffeine intake during the perinatal period promotes short- and long-term sex-dependent hormonal and behavior changes in the offspring

Caffeine for apnea and prevention of neurodevelopmental impairment in preterm infants: systematic review and meta-analysis

Caffeine: The Story beyond Oxygen-Induced Lung and Brain Injury in Neonatal Animal Models—A Narrative Review

Caffeine citrate improves outcomes of apnea of prematurity based on gestational ages

Caffeine exposure in utero is associated with structural brain alterations and deleterious neurocognitive outcomes in 9-10 year old children

Effects of caffeine on cerebral cortical activity in preterm infants

Maternal caffeine intake during pregnancy and child neurodevelopment up to eight years of age—Results from the Norwegian Mother, Father and Child Cohort Study

Can mothers consume caffeine? The issue of early life exposure and metabolic changes in offspring

The neuroprotective effect of exogen melatonin upon fetal hippocampus damage caused by high‐dose caffeine administration in pregnant rats

Caffeine exposure during pregnancy, small for gestational age birth and neonatal outcome - results from the Norwegian Mother and Child Cohort Study

Antioxidative effects of caffeine in a hyperoxia-based rat model of bronchopulmonary dysplasia

Caffeine: how early is too early?

[Safety and Efficacy of Caffeine Use Started at Different Time in Preterm Infants: a Multicenter Study in Jiangsu Province, China].